Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of BHV-3000 rimegepant compared to a placebo for treating moderate or severe migraine attacks in children and adolescents aged 6 to under 18 years. This Phase 3 study focuses on acute treatment for pediatric migraine, including cases with or without aura, aiming to better understand how well rimegepant relieves migraine pain and associated symptoms shortly after dosing. Participants are randomly assigned to receive either BHV-3000 at doses of 75 mg or 50 mg orally disintegrating tablet ODT or a matching placebo tablet. The study uses a triple-blind design to compare outcomes between these groups. The trial includes children and adolescents who experience 1 to 8 moderate or severe migraine attacks monthly, with attacks lasting over 3 hours. Some participants may continue stable preventive migraine medications except CGRP antagonists. The study monitors patients during the acute migraine attack treatment phase. During the study, participants will be assessed for pain freedom two hours after dosing as the primary outcome, as well as secondary outcomes such as freedom from the most bothersome migraine symptoms, need for rescue medication within 24 to 48 hours, sustained pain freedom, and ability to function normally. Safety and efficacy data will be collected throughout. The total duration of participation varies depending on individual treatment and follow-up requirements, with the primary completion planned by January 2029.